Impact of PCa Risk on PCa Early Detection
A. Karim Kader, MD, PhD, discusses prostate cancer risk, addressing PSA screening limitations and benefits of risk-adapted screening.
Read MoreSelect Page
Posted by A. Karim Kader, MD, PhD | Jan 2023
A. Karim Kader, MD, PhD, discusses prostate cancer risk, addressing PSA screening limitations and benefits of risk-adapted screening.
Read MorePosted by Daniel P. Petrylak, MD | Jan 2023
Daniel P. Petrylak, MD, explores immune checkpoint inhibitors for the management of bladder cancer, especially metastatic urothelial carcinoma.
Read MorePosted by Gerald L. Andriole, Jr., MD | Jan 2023
Gerald L. Andriole, Jr., MD, discusses micro-ultrasound, describing it as fast, flexible, and accurate, with real-time visualization.
Read MorePosted by Fernando J. Kim, MD, MBA, FACS | Jan 2023
Fernando J. Kim, MD, MBA, FACS, discusses his more than 23 years of experience caring for underserved and vulnerable populations.
Read MorePosted by Phillip J. Koo, MD | Jan 2023
Phillip J. Koo, MD, advises urologists and oncologists on prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) imaging.
Read More